Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure
Cureus · 29.10.2026
DOI: 10.7759/cureus.118783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 29.10.2026. Verfasst von Yomara Huertas Gómez und 6 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gómez, Y. H., Macías, R. F., Cancio, S. I. M., González, P. V., Serrano, L. R., Figueroa, M. A., & Colón, E. (2026). Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure. Cureus. https://doi.org/10.7759/cureus.118783
Vancouver
Gómez YH, Macías RF, Cancio SIM, González PV, Serrano LR, Figueroa MA, et al. Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure. Cureus. 2026. doi:10.7759/cureus.118783
BibTeX
@article{Gmez2026,
author = {Gómez, Yomara Huertas and Macías, Robert Ferrer and Cancio, Sebastián I Morales and González, Paola Vega and Serrano, Laura Rivera and Figueroa, Marialexandra Addarich and Colón, Eduardo},
title = {Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.118783}
}
EUVIMED